Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkEffect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial

Selecting effective antidepressants for the treatment of major depressive disorder is an imprecise practice. With remission rates of about 30% after the initial therapy selection, there is a need to uncover biomarkers able to predict treatment response. This study looked at pharmacogenomic testing for drug-gene interactions to guide treatment selection. Unfortunately, they did not find significantly improved outcomes.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form